<?xml version="1.0" encoding="UTF-8"?>
<p>Novel anti-IL23 agents, such as guselkumab, risankizumab, and tildrakizumab have been approved for the treatment of psoriasis and are currently under investigation for psoriatic arthritis. No literature data on their use in the setting of HBV infection are available and, thus, no relevant recommendations exist.</p>
